Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine

Volumn 29, Issue 3, 2001, Pages 503-510

  Abraham, E ^a   Laterre, P F ^a   Garbino, J ^a   Pingleton, S ^a   Butler, T ^a   Dugernier, T ^a   Margolis, B ^a   Kudsk, K ^a   Zimmerli, W ^a   Anderson, P ^a   Reynaert, M ^a   Lew, D ^a   Lesslauer, W ^a   Passe, S ^a   Cooper, P ^a   Burdeska, A ^a   Modi, M ^a   Leighton, A ^a   Salgo, M ^a   Van der Auwera, P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Clinical trial; Early septic shock; Human recombinant p55 tumor necrosis factor receptor immunoglobulin G1 fusion protein; Lenercept; Severe sepsis; Tumor necrosis factor; Tumor necrosis factor p55 receptor

Indexed keywords

INTERLEUKIN 6; LENERCEPT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035100346     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200103000-00006     Document Type: Article

References (14)

1. The pathogenesis of septic shock
2. The pathophysiology of tumor necrosis factors
3. Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense?
4. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality
5. Protection against endotoxic shock by a tumor necrosis factor immunoadhesin
6. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: Stoichiometry of binding to TNFα and TNFβ and inhibition of TNF activity
7. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDA TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081
8. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
9. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: A randomized controlled multicenter trial
10. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion protiens in an animal model of Gram-negative sepsis
11. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
12. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenecerpt and their extrapolation to humans
13. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: Comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia
14. Anti-inflammatory therapies to treat sepsis and septic shock: A reassesment